The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
 
Yuankai Shi
No Relationships to Disclose
 
Hai-Qiang Mai
No Relationships to Disclose
 
Chuanben Chen
No Relationships to Disclose
 
Ying Wang
No Relationships to Disclose
 
Jingao Li
No Relationships to Disclose
 
Hekun Jin
No Relationships to Disclose
 
Xingchen Peng
No Relationships to Disclose
 
Peng Zhang
No Relationships to Disclose
 
Shenhong Qu
No Relationships to Disclose
 
Jianli Huang
No Relationships to Disclose
 
Yu-Xiang He
No Relationships to Disclose
 
Dong-Ping Chen
No Relationships to Disclose
 
Suming Pan
No Relationships to Disclose
 
Jinsheng Hong
No Relationships to Disclose
 
Ning Zhang
No Relationships to Disclose
 
Feng Lei
No Relationships to Disclose
 
Desheng Hu
No Relationships to Disclose
 
Yan Qing
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd
 
Xiaoping Jin
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd
 
Junyou Ge
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd